|
Aim Immunotech Inc (NYSEAMER: AIM) |
|
Aim Immunotech Inc
AIM's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Aim Immunotech Inc 's sales fell
by -23.91 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 780
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 13.29 %
Aim Immunotech Inc net loss decreased from $-8 millions, to $-4 millions in III. Quarter 2024,
• More on AIM's Growth
|
|
Aim Immunotech Inc realized a net loss in trailing twelve months.
Aim Immunotech Inc realized cash reduction of $ -0.25 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 45.23.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.69.
• More on AIM's Valuation
|
|
|
|
|
Aim Immunotech Inc realized net loss in trailing twelve months.
Aim Immunotech Inc realized cash outflow of $ -0.25per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 45.23.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.69.
Aim Immunotech Inc Price to Book Ratio is at 2.95 higher than Industry Avg. of -0, and higher than S&P 500 Avg. of 0.02
• More on AIM's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com